Next Article in Journal
The Effect of Postoperative Hyperbaric Oxygen Treatment on Intra-Abdominal Adhesions in Rats
Next Article in Special Issue
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients
Previous Article in Journal
Four Novel Cellulose Synthase (CESA) Genes from Birch (Betula platyphylla Suk.) Involved in Primary and Secondary Cell Wall Biosynthesis
Previous Article in Special Issue
Environmental Risk Factors for Multiple Sclerosis: A Review with a Focus on Molecular Mechanisms
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2012, 13(10), 12213-12223; doi:10.3390/ijms131012213

Interferon-β1b Increases Th2 Response in Neuromyelitis Optica

1
Division of Neurology, Department of Internal Medicine I, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan
2
Department of Central Laboratory, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan
*
Author to whom correspondence should be addressed.
Received: 6 August 2012 / Revised: 12 September 2012 / Accepted: 20 September 2012 / Published: 25 September 2012
(This article belongs to the Special Issue Recent Advances in the Research of Multiple Sclerosis)
View Full-Text   |   Download PDF [348 KB, uploaded 19 June 2014]   |  

Abstract

A Japanese randomized controlled study showed that Interferon â (IFN-â1b) therapy is clinically effective in decreasing the frequency of attacks in multiple sclerosis (MS), even in optico-spinal MS (OSMS). However, recent studies have shown that IFN-â (IFN-â1a/IFN-â1b) treatment was not effective in neuromyelitis optica (NMO) patients and that the diminished benefit of IFN-â treatment in NMO may be due to different immune responses to IFN-â. We determined longitudinally the expression of CCR5, CXCR3 and CCR4 on CD4+ T and CD8+ T cells in the blood from patients with NMO and MS treated with IFN-â1b. During a 12-month period of IFN-â1b therapy, the annualized relapse rate decreased in MS patients but not in NMO patients. There was no significant difference in the expression of the chemokine receptors between NMO and MS at baseline. The percentages of CD4+CCR5+ and CD4+CXCR3+ T cells, representative of the Th1 response, were decreased in both NMO and MS after treatment. The percentage of CD4+CCR4+ T cells, representative of the Th2 response, was decreased in MS, but those for NMO was significantly increased compared with the pretreatment levels. Our results indicate that IFN-â1b-induced up-modulation of the Th2 response in NMO patients may be the source of differences in the therapeutic response to IFN-â1b therapy. In the present study, Th2 predominance is involved in the pathogenesis of NMO.
Keywords: neuromyelitis optica; multiple sclerosis; IFN-â1b; chemokine receptor; CCR5; CXCR3; CCR4; Th1; Th2 neuromyelitis optica; multiple sclerosis; IFN-â1b; chemokine receptor; CCR5; CXCR3; CCR4; Th1; Th2
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Nakajima, H.; Hosokawa, T.; Doi, Y.; Ikemoto, T.; Ishida, S.; Kimura, F.; Hanafusa, T. Interferon-β1b Increases Th2 Response in Neuromyelitis Optica. Int. J. Mol. Sci. 2012, 13, 12213-12223.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top